Brief: NLS Pharmaceutics Announces Patent Issuance In Europe
05/05/2021 13:42
May 5 (Reuters) - NLS Pharmaceutics AG NLSP.O :
* NLS PHARMACEUTICS ANNOUNCES PATENT ISSUANCE IN EUROPE FOR
ITS
MAZINDOL CONTROLLED-RELEASE FORMULATION (MAZINDOL CR)
* NLS PHARMACEUTICS AG - REMAIN ON TRACK TO INITIATE
PROSPECTIVE
PHASE 2 CLINICAL STUDY FOR QUILIENCE THIS SUMMER
Source text for Eikon: ID:nPn5kDr9Wa
Further company coverage: NLSP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NewcelX AG
See all newsBrief: Newcelx Announces Pricing Of $1.4 Million Equity Financing At 20% Premium Pricing
Brief: Newcelx Submits Pre-IND Package To FDA For NCEL-101 For Treatment Of Type 1 Diabetes
Brief: Newcelx Updates Corporate Presentation To Highlight Type 1 Diabetes Flagship Program
U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences
U.S. STOCKS ON THE MOVE-Intel, Tempus AI, Boeing